|
Mutation Information
|
Mutation Site
|
Y118F |
|
Mutation Type
|
Amino acid level |
|
Gene/Protein/Region Type
|
C |
|
Genotype/Subtype
|
A |
|
Viral Reference
|
X02763
|
|
Relevant Drug
|
JNJ‐6379 |
|
Country
|
Asia‐Pacific;Europe |
Literature Information
|
PubMed PMID
|
32579776
|
|
Disease
|
Chronic hepatitis B
|
|
Published Year
|
2020 |
|
Journal
|
Journal of viral hepatitis |
|
Title
|
Virology analysis of chronic hepatitis B virus-infected patients treated for 28 days with JNJ-56136379 monotherapy. |
|
Author
|
Verbinnen T,Hodari M,Talloen W,Berke JM,Blue D,Yogaratnam J,Vandenbossche J,Shukla U,De Meyer S,Lenz O |
|
Evidence
|
Two JNJ-6379-treated patients carried a Y118F baseline core polymorphism known to reduce JNJ-6379 activity in vitro (FC = 6.6) and had HBV DNA declines of 2.77 (75 mg) and 2.19 log10 IU/mL (150 mg) at the end of treatment.
|
|
|
HBV Mutation Detail Information